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Inherited deafness is clinically and genetically heterogeneous.We recentlymappedDFNB86, a locus associatedwith nonsyndromic deaf-
ness, to chromosome 16p. In this study, whole-exome sequencing was performed with genomic DNA from affected individuals from
three large consanguineous families in which markers linked to DFNB86 segregate with profound deafness. Analyses of these data re-
vealed homozygous mutation c.208G>T (p.Asp70Tyr) or c.878G>C (p.Arg293Pro) in TBC1D24 as the underlying cause of deafness
in the three families. Sanger sequence analysis of TBC1D24 in an additional large family in which deafness segregates withDFNB86 iden-
tified the c.208G>T (p.Asp70Tyr) substitution. These mutations affect TBC1D24 amino acid residues that are conserved in orthologs
ranging from fruit fly to human. Neither variant was observed in databases of single-nucleotide variants or in 634 chromosomes
from ethnicallymatched control subjects. TBC1D24 in themouse inner ear was immunolocalized predominantly to spiral ganglion neu-
rons, indicating that DFNB86 deafness might be an auditory neuropathy spectrum disorder. Previously, six recessive mutations in
TBC1D24were reported to cause seizures (hearing loss was not reported) ranging in severity from epilepsy with otherwise normal devel-
opment to epileptic encephalopathy resulting in childhood death. Two of our four families in which deafness segregates with mutant
alleles of TBC1D24 were available for neurological examination. Cosegregation of epilepsy and deafness was not observed in these two
families. Although the causal relationship between genotype and phenotype is not presently understood, our findings, combined with
published data, indicate that recessive alleles of TBC1D24 can cause either epilepsy or nonsyndromic deafness.Hearing loss occurs in approximately 0.2% of newborns,
and two-thirds of these cases appear to have a genetic
cause.1 The prevalence of hearing loss increases with age,
and there are hundreds of syndromes that include deafness
as one feature of a complex phenotype (OMIM, see Web
Resources). Additionally, 114 loci have been genetically
mapped for nonsyndromic deafness segregating as either
a dominant (DFNA) or a recessive (DFNB) trait (Hereditary
Hearing Loss Homepage, see Web Resources).1,2 For
approximately half of these loci, the genes with mutations
that result in nonsyndromic deafness have been identified.
The wild-type alleles of these genes subserve a myriad of
cellular functions that span the gamut from transcription
factors to extracellular matrix proteins,2,3 and one-third
of them encode proteins that interact with actin and are
crucial for mechanotransduction of sound in the inner
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144 The American Journal of Human Genetics 94, 144–152, January 2logical functions described in the auditory system,6,7 there
are only a few examples of genes that have a pattern of
expression limited to the inner ear.8,9 In fact, many genes
with mutations associated with nonsyndromic deafness
do not encode inner-ear-cell-specific molecules but rather
are expressed in a variety of organ systems.10–12 For
example, ACTG1 (MIM 102560), encoding cytoplasmic
g-actin,13 and HGF (MIM 142409), encoding hepatocyte
growth factor (HGF), are associated with nonsyndromic
deafness DFNA20 (MIM 604717) and DFNB39 (MIM
608265), respectively, and show widespread expression.14
An inference from these observations is that a mutation
in any gene, no matter how widely expressed in the
body, could be a cause of a phenotypically restricted
human disorder.15,16
Genome-wide homozygositymapping of DFNB in a large
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Figure 1. Refinement of the DFNB86 Linkage Interval
The thick vertical bar represents human chromosome 16p. The
linkage interval for thedeafness segregating in eachof the four fam-
ilies is indicated by a thin vertical bar. The gray shaded region high-
lights the DFNB86 linkage interval shared by the four families.locus DFNB86 on chromosome 16p with a maximum LOD
score of 8.5.17 In this study, three additional consanguin-
eous pedigrees (DEM4221, DEM4587, and DEM4476)
from Pakistan were ascertained (inbreeding coefficients,
Table S1, available online), and their recessive deafness
was linked to DFNB86 with maximum LOD scores of
6.90, 3.26, and 5.97, respectively. The overlapping region
of homozygosity of these four pedigrees spans 2.05 Mb
and contains 121 annotated genes (Figure 1). Here, we
report that recessivemutations in TBC1D24 (TBC1 domain
family, member 24 [MIM 613577]) are the cause of the
nonsyndromic deafness (DFNB86) segregating in these
four families.
Approval for this study was obtained from the institu-
tional review boards of the Baylor College of MedicineThe Amerand Affiliated Hospitals (Houston), the National Centre
of Excellence in Molecular Biology (University of the
Punjab, Lahore), and Quaid-I-AzamUniversity (Islamabad)
and from the Combined Neuroscience Institutional
Review Board (protocol OH93-DC-0016) at the National
Institutes of Health (Bethesda). Written informed consent
was obtained from all family members participating in this
study.
Pure-tone audiometric evaluations of 4 of the 11 affected
individuals from family PKDF799 revealed profound deaf-
ness (hearing threshold R 90 dB) at all test frequencies,
whereas obligate carriers had normal hearing thresh-
olds.17 Genomic DNA samples from three affected individ-
uals (IV-23 from family PKDF799, IV-11 from family
DEM4221, and IV-6 from family DEM4476) were processed
for whole-exome sequencing (WES; Figure 2). For family
PKDF799, a TargetSeq Exome Enrichment Kit (Applied
Biosystems) was used for capturing the whole exome
(45.1 Mb), which was sequenced on an Applied Bio-
systems SOLiD5500 platform. For families DEM4221 and
DEM4476, an EZ Exome v.3.0 kit (NimbleGen) was used
for capturing ~64 Mb of protein-coding plus untranslated
expressed sequences, and massively parallel sequencing
was performed on an Illumina HiSeq. Sequence reads
generated from these libraries were filtered for quality
and were mapped to the hg19 human reference genome
(UCSC Genome Browser). For family PKDF799, mapping
and variant calling were performed with LifeScope
(Applied Biosystems). ANNOVARwas used for variant anal-
ysis.18 For families DEM4221 and DEM4476, sequence
alignment and variant calling were performed with the
Burrows-Wheeler Aligner and Genome Analysis Toolkit,
respectively. Depth of coverage and the number of DNA
variants in the threeWES data sets are summarized in Table
S2. Assuming locus homogeneity, and because there is sig-
nificant evidence of linkage between markers for DFNB86
and the deafness segregating in these families, we focused
our evaluation of the WES data sets only on DNA variants
in the smallestDFNB86 linkage interval defined bymeiotic
recombinations (Figure 1). Additional criteria for filtering
data for identifying the pathogenic variants were homozy-
gosity for a variant and an allele frequency < 1% in the
NHLBI Exome Sequencing Project (ESP) Exome Variant
Server (EVS)19 and the 1000 Genomes Project. These vari-
ants were confirmed by Sanger sequence analysis of
genomic DNA from family members, and allele fre-
quencies were obtained with the use of ethnically matched
control individuals (R148 chromosomes, Table 1).
On the basis of the criteria listed above, analyses of the
WES data sets for the three families revealed a total of
seven homozygous DNA variants within the refined
DFNB86 interval (Table 1). Five of the seven variants
were not considered to be pathogenic. A synonymous
variant, c.3060G>A (p.Ala1020Ala), in CACNA1H (MIM
607904) is a polymorphism in the Pakistani population.
The c.1520G>A (p.Arg507His) variant in IGFALS (MIM
601489) was not studied further because the affectedican Journal of Human Genetics 94, 144–152, January 2, 2014 145
Figure 2. Four Families in which Deafness Cosegregates with Missense Mutations in TBC1D24
(A) Profound deafness in three families cosegregates with the c.208G>T (p.Asp70Tyr) variant in TBC1D24. Representative chromato-
grams from wild-type and mutant sequences are shown. Altered nucleotides and affected residues are highlighted in gray. Genotypes
of the participating family members are shown below each symbol in single-letter amino acid nomenclature. Individuals diagnosed
with either seizures or epilepsy are highlighted by a gray rectangle. In family PKDF799, 10 of 11 deaf individuals have no history of
seizures. Deaf female IV-13 had febrile seizures at the age of 8 years. In family DEM4587, there is no history of seizures in any of the
eight clinically investigated family members, indicated by asterisks. Clinical re-evaluation of families DEM4221 and DEM4476 was
not possible.
(B) Deaf individuals from family DEM4476 are homozygous for the c.878G>C (p.Arg293Pro) variant in TBC1D24, whereas normal-
hearing parents and siblings of affected family members are heterozygous carriers of this mutation.amino acid is not evolutionarily conserved and the substi-
tution is predicted to not be detrimental by five in silico
programs, including MutationTaster, PolyPhen-2, and
SIFT. The synonymous variant c.720G>A (p.Ser240Ser) in
PRSS27 (MIM 608018) was not detected in 490 ethnically
matched control chromosomes but has an allele frequency
of 0.47% in the EVS (Table 1). A transition mutation,
c.973C>T (p.Arg280Trp) in THOC6 (MIM 615403), identi-
fied in family DEM4221 does not cosegregate with deaf-
ness, further refining the linkage interval of this family
(Figure 1).
TBC1D24 was the only gene in which homozygous
pathogenic mutations were found in the exome data sets
of all three families (Table 1). Deaf members of families
PKDF799 and DEM4221 are homozygous for a transver-
sion mutation, c.208G>T, predicted to cause a p.Asp70Tyr
substitution. Deaf members of family DEM4476 are
homozygous for c.878G>C (p.Arg293Pro) in TBC1D24.
We also Sanger sequenced the coding exons of TBC1D24
in affected individuals from the fourth family, DEM4587,
and found the c.208G>T (p.Asp70Tyr) mutation. The146 The American Journal of Human Genetics 94, 144–152, January 2c.208G>T mutation occurs on a haplotype spanning
477 kb shared among three families (Table S3). The two
missense alleles of TBC1D24 cosegregate with deafness
in these families, are absent from the EVS and 1000
Genomes Project, and were not observed in at least
634 control chromosomes from ethnically matched
individuals (Table 1). The substitutions p.Asp70Tyr and
p.Arg293Pro affect residues conserved in orthologs of
TBC1D24 from Drosophila melanogaster to Homo sapiens
(Figure 3A). The p.Asp70Tyr substitution is predicted to
be ‘‘damaging’’ to TBC1D24 function by MutationTaster,
Mutation Assessor, LRT, SIFT, and PolyPhen-2. The
p.Arg293Pro variant was assessed by SIFT as ‘‘tolerated’’
but was predicted to be ‘‘damaging’’ by the other four algo-
rithms and is not reported in the EVS or 1000 Genomes
Project. However, the EVS does contain two variants
for the Arg293 codon: c.877C>T (p.Arg293Cys) and
c.878G>A (p.Arg293His). In the ~6,500 EVS exomes,
a heterozygous p.Arg293Cys substitution was detected
once among 12,838 chromosomes, whereas heterozy-
gosity for p.Arg293His was detected seven times among, 2014
Table 1. Homozygous Variants Identified within the DFNB86 Interval
Gene Varianta mRNA Changeb
Deduced Effect on
Proteinb Family Mutation Type
Allele Frequency
in EVSc
Allele Frequency
in Control
Chromosomes
CACNA1H g.1257427G>A c.3060G>A
(NM_001005407.1)
p.Ala1020Ala
(NP_001005407.1)
PKDF799 synonymous 3/12,229 2/174
IGFALS g.1841013C>T c.1520G>A
(NM_001146006.1)
p.Arg507His
(NP_001139478.1)
DEM4476 missense 0/12,875 -d
TBC1D24 g.2546357G>T c.208G>T
(NM_001199107.1)
p.Asp70Tyr
(NP_001186036.1)
PKDF799 missense 0/12,875 0/682
TBC1D24 g.2546357G>T c.208G>T
(NM_001199107.1)
p.Asp70Tyr
(NP_001186036.1)
DEM4221 missense 0/12,875 0/682
TBC1D24 g.2547027G>C c.878G>C
(NM_001199107.1)
p.Arg293Pro
(NP_001186036.1)
DEM4476 missense 0/12,875 0/634
PRSS27 g.2762774C>T c.720G>A
(NM_031948.3)
p.Ser240Ser
(NP_114154.1)
PKDF799 synonymous 61/12,875 0/490
PRSS27 g.2762774C>T c.720G>A
(NM_031948.3)
p.Ser240Ser
(NP_114154.1)
DEM4221 synonymous 61/12,875 0/490
SRRM2 g.2819161_
2819163delTCT
c.7897_7899delTCT
(NM_016333.3)
p.Ser2633del
(NP_057417.3)
DEM4476 in-frame deletione 49/12,396 1/290
THOC6 g.3077605C>T c.973C>T
(NM_024339.3)
p.Arg280Trpf
(NP_077315.2)
DEM4221 missense 0/12,875 0/148
aCoordinates are based on the hg19 human reference sequence (UCSC Genome Browser).
bRefSeq accession numbers are shown in parentheses.
cNHLBI Exome Sequencing Project (ESP) Exome Variant Server.
dArg507 is not conserved in mouse, rat, or dog. The substitution of His for Arg507 is predicted to be neutral by MutationTaster, PolyPhen-2, SIFT, LRT, and
MutationAssessor.
eThis deletion of three nucleotides is one of several similar indels previously reported in the EVS as common SNPs resulting in deletion or insertion of one or more
serine residues in a stretch of 42 consecutive serines.
fDoes not cosegregate with deafness in family DEM4221.12,828 chromosomes. Both of these rare variants are pre-
dicted by in silico programs to be damaging to TBC1D24
function, suggesting a crucial role for Arg293 in the normal
function of TBC1D24.
Human TBC1D24 has eight exons, and the longest
mRNA encodes a protein of 559 amino acids (Figure 3B).
In mammals, TBC1D24 is one of 42 TBC (Tre-2, Bub2,
Cdc16)-domain-containing family members.20 TBC do-
mains have approximately 200 residues that are conserved
in amino acid sequence from yeast to human.21 The
p.Asp70Tyr substitution is located within the TBC domain
of TBC1D24 (Figure 3B). Although the crystal structure of
TBC1D24 is not known, the sequence can be compared
with that of other TBC domains that have X-ray crystal
structures available. Comparison with the sequence of
TBC1D4 suggests that the altered residue Asp70 is analo-
gous to residue Asp950 of TBC1D4 (3QYB).22 This residue
is located in a loop between two helices, termed a3 and
a4, in the TBC1D4 structure. The boundaries of this loop
vary significantly between different TBC domains, and
high B-factors indicate a relatively large degree of flexibility
or disorder in this region. Although it is possible that the
loopmight be the site of interaction with a different region
of TBC1D24 or a binding region for another protein, no
specific roles for the loop have yet been identified.
Some TBC-domain-containing proteins have been
shown to function as GTPase-activating proteins (GAPs),The Amerwhich accelerate the intrinsic rate of GTP hydrolysis of
specific Rab-GTPases.23 When the GTP of a Rab-GTPase is
hydrolyzed to GDP by a GAP, the protein becomes inactive
until the GDP is exchanged for GTP by another class of
regulatory proteins termed guanine nucleotide exchange
factors.20 Thus, GAPs are involved in the regulation of
numerous membrane-trafficking and sorting processes of
vesicles by modulating the activity of Rab-GTPases.20 A
direct Rab-GTPase target of TBC1D24 has not been re-
ported and might not exist. In yeast, the TBC-domain-
containing protein Gyp1p (RefSeq accession number
NP_014713.1) has been demonstrated to require an argi-
nine at residue 343 for its Rab-GAP-stimulating activity.23
Clustal Omega alignment of the TBC domains of yeast
Gyp1p and human TBC1D24 shows that there is a gluta-
mine rather than a catalytic arginine at residue 100 of
TBC1D24, suggesting that TBC1D24 lacks Rab-GAP
GTPase-stimulating activity.20 However, ARF6 (ADP-ribo-
sylation factor 6) was reported to be a partner of
TBC1D24 and could provide GTPase activity.24
To begin to understand wild-type TBC1D24 function in
normal hearing, we examined its pattern of expression,
alternative transcript splicing, and immunolocalization
of TBC1D24 in the mouse inner ear. Although not previ-
ously reported in the auditory system, human TBC1D24
is expressed in a variety of tissues, including the heart,
liver, kidney, stomach, lungs, and brain.24 The NCBIican Journal of Human Genetics 94, 144–152, January 2, 2014 147
Figure 3. Structure of TBC1D24 and Amino Acid Conservation of the Affected TBC1D24 Residues
(A) ClustalW2 alignment of TBC1D24 orthologs shows that the two DFNB86-associated mutations affect conserved residues (red font).
Amino acid residue identity and similarity percentages were calculated for full-length TBC1D24.
(B) Graphic representation of TBC1D24 structure (left) and its encoded protein (right). The red bar above the TLDc domain represents the
epitope for the commercial antibody (Abcam, ab101933) that we used in Figure 4. DFNB86-associated mutations are shown above the
diagram, and epilepsy-associated mutations are shown below. Tall and short gray boxes represent coding exons and UTRs of the tran-
scribed gene, respectively. Horizontal lines joining the gray boxes denote introns. The longest isoform of TBC1D24was used as the refer-
ence sequence for mutation nomenclature (RefSeq NM_001199107.1 and NP_001186036.1). c. 1544C>T (p.Ala515Val) is renamed here
according to the longest isoform but was originally reported as c.1526C>T (p.Ala509Val) on the basis of a shorter isoform of TBC1D24
(Falace et al.24).Gene database lists eight splice variants composing two
protein isoforms (a and b) of mouse Tbc1d24 (NCBI Gene
ID 224617). Isoforms a and b are predicted to encode 561
amino acids (63.2 kDa) and 555 amino acids (62.6 kDa),
respectively. We investigated mouse Tbc1d24 mRNA
expression after preparing a cDNA library from P12 mouse
inner-ear tissue. We used forward and reverse PCR primers
complementary to the 50 UTR and 30 UTR of the full-length
transcript to amplify and characterize splice isoforms of
this gene (Figure S1). Agarose gel electrophoresis separated
the PCR product into five bands of distinct sizes (data not
shown) that were individually isolated, cloned, and Sanger
sequenced. We detected nine alternatively spliced tran-
scripts, including the previously reported isoforms a and
b, of protein-coding exons of Tbc1d24 (Figure S1). Isoforms
a–e include large exon 5, which encodes 57% of the full-
length protein, including the translation initiation codon.
However, exon 5 is not included in isoforms f–i. If trans-
lated, these shorter transcripts would utilize in-frame
ATG codons that do not satisfy the consensus (3A
and þ4G) for a Kozak start site,25 which is not an absolute
requirement for translation initiation. If these short iso-
forms are also expressed in humans, they would not be
affected by the two TBC1D24 missense mutations associ-
ated with DFNB86 deafness.
Immunoblot analysis of P12 mouse brain and cochlea
lysates with the use of a commercially available TBC1D24
antibody (Abcam, ab101933) revealed a signal at 60 kDa,
consistent with the expected size for the two previously
reported TBC1D24 isoforms. There was also a signal at148 The American Journal of Human Genetics 94, 144–152, January 220 kDa in untransfected COS-7 cells and in mouse brain
and cochlear lysates. The 20 kDa signal might be the short
isoform f, which includes the epitope recognized by
TBC1D24 antibody ab101933 (Figure S1). To determine
whether this antibody recognizes TBC1D24, we included
a lysate from COS-7 cells transfected with an expression
vector encoding pEGFP-TBC1D24 (full length) in the
immunoblot analysis, and the expected product corre-
sponding to EGFP-TBC1D24 (26.9þ63.2 kDa)was detected
at approximately 90 kDa (Figure S1).
To investigate TBC1D24 localization in P30mouse inner-
ear, we immunolabeled26 cryosections with the TBC1D24
antibody and counterstained them with DAPI and rhoda-
mine phalloidin. The strong signal for TBC1D24 was
observed in spiral ganglion cells, a collection of neurons
critical for hearing and balance (Figure 4).
In addition to a TBC domain, the only other predicted
domain in TBC1D24 is a C-terminal TLDc domain (TBC,
LysM, domain catalytic). Neither of the two TBC1D24
missense mutations associated with deafness alters the
TLDc domain. There are four other human TLDc-domain-
containing proteins, including NCOA7 and OXR1, both of
which have been demonstrated to defend cells against
oxidative stress.27,28 Interestingly, the mouse OXR1 TLDc
domain alone is sufficient to protect granule cells of
the cerebellum against oxidative stress.27 Clustal Omega
alignment of the 163 residues of the TLDc domain of
mouse OXR1 shows 66% similarity to the TLDc domain
of human TBC1D24. Given the reported role of TLDc
domains, an additional wild-type function of TBC1D24, 2014
Figure 4. TBC1D24 Is Found in Spiral
Ganglion Neurons of the Mouse Inner Ear
(A) TBC1D24 antibody binds to spiral gan-
glion cells in the P30 cochlea.
(B) The corresponding signal is absent in a
control experiment with no added pri-
mary antibody.
(C) A higher-magnification image reveals
TBC1D24 antibody binding to the cell
body and axonal projections of spiral
ganglion. Scale bars in (A) and (B) repre-
sent 40 mm, whereas that in (C) repre-
sents 10 mm.might be to help safeguard spiral ganglion neurons against
oxidative stress.
Assuming that p.Asp70Tyr and p.Arg293Pro cause deaf-
ness as a result of an altered function of TBC1D24 in the
spiral ganglion neurons of the inner ear, DFNB86 deafness
might be an auditory neuropathy spectrum disorder.29–31
These disorders are audiologically defined by abnormal
auditory brainstem response (ABR) waveforms and inter-
peak intervals in combination with normal otoacoustic
emissions (OAEs).32 These findings reflect an underlying
lesion in the afferent auditory pathway, which includes
the auditory nerve, the afferent synapse with the inner
hair cell, or the inner hair cell itself. In the absence of
afferent stimulation, the remaining hair cells and organ
of Corti can eventually degenerate secondarily. Unfortu-
nately, we were not able to obtain OAE and ABR data
from any of our subjects. However, mouse models of
DFNB86might allow testing of the hypothesis that the pri-
mary lesion in TBC1D24 affects spiral ganglion neurons.
Four independent publications have described families
in which epilepsy, with varying degrees of severity, segre-
gates with recessive mutations in TBC1D24 (Figure 3B
and Table 2). Individuals from an Italian family affected
by familial infantile myoclonic epilepsy (FIME [MIM
605021]) were found to be compound heterozygous for
c.439G>C (p.Asp147His) and c.1544C>T (p.Ala515Val)
in TBC1D24.24 In another family (ethnicity not reported),
two siblings presented with malignant migrating partial
seizures of infancy (MIM 605021) as a result of compound
heterozygosity for c.468C>A (p.Cys156*) and c.686T>C
(p.Phe229Ser) in TBC1D24.35 In an Arab family, four sib-
lings with a focal epilepsy and intellectual disability syn-The American Journal of Human Gdrome (MIM 605021) were homozy-
gous for a c.751T>C (p.Phe251Leu)
allele of TBC1D24.34 Finally, in a
family from Turkey, a homozygous
2-nucleotide deletion located in
cassette exon 3 of TBC1D24 (Fig-
ure 3B) caused myoclonic epilepsy
and severe neurodegeneration culmi-
nating in childhood death between
the ages of 1.5 and 7 years.33
Do mutations in TBC1D24 cause
either epilepsy without hearing lossor hearing loss without epilepsy? The four reports docu-
menting seizure disorders do not mention hearing loss in
epileptic individuals.24,33–35 In the four DFNB86-affected
families, epilepsy might initially have gone undetected
given that a family history of seizures was not an element
of ascertainment. Therefore, we reassessed 15 deaf subjects
in our study for a history of epilepsy. We were able to
obtain clinical data for only two of the four families
(DEM4587 and PKDF799, Figure 2). In family DEM4587,
no history of seizures was reported for the eight individuals
indicated by asterisks in Figure 2A. Brain MRI and electro-
encephalography (EEG) of deaf individuals IV-1 and IV-2
were normal. In family PKDF799, a history regarding sei-
zures and epilepsy was obtained from 25 individuals, and
EEG was performed for individuals III-12, IV-8, IV-12, IV-
14, IV-15, and IV-17 (Figure 2A). EEG of a 16-year old
individual with normal hearing (IV-12) was consistent
with potential seizure activity, but he reported not ever
having a seizure. Individual IV-8 (18 years old), who has
normal hearing, has seizures that began when she was
approximately 3 years of age and now occur two to three
times a month. At the age 8 years, a third family member,
an 18-year-old deaf individual (IV-13) had seizures that, ac-
cording to her parents, were associated with a fever, which
is common in children with hyperpyrexia. She has not had
a seizure since then. The remaining 22 evaluated family
members have no history of seizures. Individuals IV-8
and IV-12 are heterozygous for c.208G>T (p.Asp70Tyr) in
TBC1D24, and their audiograms showed normal hearing
thresholds (data not shown). For p.Asp70Tyr carrier IV-8,
all eight exons of TBC1D24 were sequenced and no other
variants of this gene were found. To date, only recessiveenetics 94, 144–152, January 2, 2014 149
Table 2. TBC1D24 Mutations and Associated Phenotypes
Origin Phenotype Mutationa
Zygosity in Affected
Individuals Reference
Pakistan nonsyndromic deafness c.208G>T (p.Asp70Tyr) homozygous this study
Pakistan nonsyndromic deafness c.878G>C (p.Arg293Pro) homozygous this study
Turkey myoclonic epilepsy, dystonia, developmental and
neurological disability, childhood lethality
c.969_970delGT (p.Ser324Thrfs*3) homozygous Guven et al.33
Israel focal epilepsy and intellectual disability c.751T>C (p.Phe251Leu) homozygous Corbett et al.34
Italy myoclonic and generalized tonic-clonic seizures,
photosensitivity
c.439G>C (p.Asp147His) compound heterozygous Falace et al.24
c.1544C>T (p.Ala515Val)b
Not reported malignant migrating partial seizures of infancy c.468C>A (p.Cys156*) compound heterozygous Milh et al.35
c.686T>C (p.Phe229Ser)
aNomenclature in this table is based on the longest isoform (RefSeq NM_001199107.1 and NP_001186036.1) of TBC1D24.
bReported as p.Ala509Val on the basis of a shorter isoform (RefSeq NP_065756.1) of TBC1D24.mutations in TBC1D24 have been associated with epi-
lepsy.24,33–35 Only one of two individuals with epilepsy
in family PKDF799 is both deaf and homozygous for a mu-
tation in TBC1D24. The World Health Organization re-
ports that the world prevalence of epilepsy is 0.4%–1%.
Given the high prevalence of epilepsy, especially in devel-
oping countries, we suspect that this association is a coin-
cidence.
The localization of TBC1D24 in neurons links two
distinct phenotypes, epilepsy and deafness. In the inner
ear, TBC1D24 was immunolocalized predominantly in spi-
ral ganglion neurons (Figure 4), whereas in the brain,
TBC1D24 mRNA was localized by in situ hybridization to
the hippocampus and cortex.24 Falace and coauthors also
reported that ARF6, a member of a family with GTPase
activity, is a partner of TBC1D24 and is involved in neurite
outgrowth.24 ARF6 is also a component of a complex
with scaffold protein GAB1 (GRB2-associated binding
protein 1), GGA3 (golgi-associated, gamma adaptin ear-
containing Arf-binding protein 3), and CRK (v-crk avian
sarcoma virus CT10 oncogene homolog). This complex
mediates the MET (receptor tyrosine kinase) internaliza-
tion and recycling pathway36,37 only after MET is activated
by its ligand HGF. We previously reported that non-pro-
tein-coding recessive mutant alleles of HGF cause human
nonsyndromic deafness DFNB39.14 The p.Asp147His epi-
lepsy-associated substitution, located in the TBC domain
of TBC1D24, reduces its binding to ARF6.24 It remains to
be determined whether ARF6 is also localized to spiral gan-
glion neurons and whether or not the deafness-associated
substitution p.Asp70Tyr alters ARF6 regulatory activity.
Assuming that there is normal hearing in epileptic indi-
viduals with recessive mutations in TBC1D24,24,33–35 it is
intriguing that different recessive alleles of TBC1D24 cause
two distinct phenotypes, deafness and epilepsy. One possi-
bility is that genetic background modifies the phenotypic
outcome of TBC1D24mutations. Alternatively, differences
in mutant alleles of TBC1D24 might directly account for
the different phenotypic outcomes, epilepsy and deafness.150 The American Journal of Human Genetics 94, 144–152, January 2Mouse Tbc1d24 knockin alleles engineered to model the
human mutations could address these questions.Supplemental Data
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